pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
491
stories
2d
STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
stat
2d
Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
fiercebiotech
3d
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
biopharma dive
3d
Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
biospace
4d
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
4d
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
biopharma dive
4d
In China’s shadow, Pfizer CEO calls for AI savings to bolster Big Pharma
biospace
4d
5 acquisitions that forced Big Pharmas to co-parent
biospace
5d
Roche breast cancer pill cleared by FDA
biopharma dive
5d
Kyntra axes mid-stage ADC, adding to years of stumbles
fiercebiotech
6d
AstraZeneca, Alexion's myasthenia gravis treatment enters crowded market
endpoints
6d
China's $40k CAR-T; Novartis and Biogen strike deals
endpoints
6d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
6d
Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test
fiercebiotech
6d
Flagship commits £100M to set up AI-focused biotech incubation outpost in London
fiercebiotech
7d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
9d
PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO
biospace
9d
AstraZeneca pulls EU filing for antibody as CHMP backs Gazyvaro in lupus
endpoints
9d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
9d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
9d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
9d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
10d
Sofinnova books biggest-ever $815M fund with an eye toward up-and-coming ‘global leaders’
fiercebiotech
10d
Deep dive: Cardiovascular calamities and catalysts
biospace
11d
Flagship merges two startups; J&J scores a bipolar mania success
endpoints
11d
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
biopharma dive
12d
AstraZeneca buys partner Omniose for bacterial vaccine technology
fiercebiotech
13d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
15d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
16d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
← prev
page 1 of 17
next →